Tag Archives: ALK+ NSCLC

May, 2017

April, 2016

  • 27 April

    Celldex Initiates Phase 1/2 Study in Squamous Cell Lung Cancer

    HAMPTON, N.J., April 27, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC) of the lung, who have …

May, 2015

  • 8 May

    Novartis’ Zykadia Receives EU Approval for Treatment of Lung Cancer

    Novartis’ lung cancer drug gained European approval for treatment of patients with non-small cell lung cancer (NSCLC). The company said that the European Commission (EC) has approved Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC previously treated with crizotinib. The European Union’s (EU) approval of …